| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Gil Yosipovitch | |
| Tejesh Patel | |||
| P2860 | cites work | The capsaicin receptor: a heat-activated ion channel in the pain pathway | Q24322558 |
| New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma | Q24615751 | ||
| The effect of topically applied aspirin on localized circumscribed neurodermatitis | Q28191659 | ||
| The neurobiology of itch | Q28247676 | ||
| TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase | Q79847967 | ||
| Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma | Q80110797 | ||
| Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice | Q80147903 | ||
| Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis | Q82825637 | ||
| Transepidermal water loss, serum IgE and beta-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis | Q83355760 | ||
| Brachioradial pruritus: report of a new case responding to gabapentin | Q83366933 | ||
| mu-Opposing actions of the kappa-opioid receptor | Q28270615 | ||
| Effects of menthol and cold on histamine-induced itch and skin reactions in man | Q28294312 | ||
| IL-31: a new link between T cells and pruritus in atopic skin inflammation | Q28295839 | ||
| Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia | Q28374767 | ||
| A TRP channel that senses cold stimuli and menthol | Q28511363 | ||
| Identification of a cold receptor reveals a general role for TRP channels in thermosensation | Q28580334 | ||
| TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms | Q30488724 | ||
| Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials | Q30677683 | ||
| Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin | Q30955557 | ||
| Treatment of prurigo nodularis with topical capsaicin. | Q30981474 | ||
| Opioid antagonists in the treatment of opioid-induced constipation and pruritus | Q31989753 | ||
| Azathioprine for atopic dermatitis. | Q34328070 | ||
| Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects | Q34415180 | ||
| Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. | Q34501307 | ||
| Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). | Q34734120 | ||
| Treatment of pruritic diseases with topical calcineurin inhibitors. | Q35166799 | ||
| Menthol: a refreshing look at this ancient compound | Q36820432 | ||
| Nocturnal itch: why do we itch at night? | Q36863597 | ||
| Neurophysiological and neurochemical basis of modern pruritus treatment. | Q37028291 | ||
| What causes itch in atopic dermatitis? | Q37208966 | ||
| NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain | Q39301276 | ||
| Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial | Q39344418 | ||
| Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). | Q39346154 | ||
| Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. | Q39355978 | ||
| Clinical characteristics of pruritus in chronic idiopathic urticaria | Q39405332 | ||
| The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group | Q39470353 | ||
| Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group | Q39481025 | ||
| Treatment of notalgia paresthetica with capsaicin. | Q39502284 | ||
| Topical capsaicin for treatment of hemodialysis-related pruritus | Q39504336 | ||
| Itch and atopic dermatitis: clinical and experimental studies | Q39513206 | ||
| Relief of experimentally induced pruritus with a novel eutectic mixture of local anaesthetic agents | Q39530205 | ||
| Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. | Q40004812 | ||
| Capsaicin-induced depletion of substance P from primary sensory neurones | Q40164536 | ||
| The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission | Q41224847 | ||
| Effect of oral naltrexone on pruritus in cholestatic patients | Q41808544 | ||
| Butorphanol for treatment of intractable pruritus | Q42680770 | ||
| Mechanisms of the sensory effects of tacrolimus on the skin | Q43123681 | ||
| Ethnic differences in pain, itch and thermal detection in response to topical capsaicin: African Americans display a notably limited hyperalgesia and neurogenic inflammation | Q43210106 | ||
| Aprepitant as an antipruritic agent? | Q43268400 | ||
| Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. | Q43872465 | ||
| Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus | Q44148036 | ||
| Effect of topical pramoxine on experimentally induced pruritus in humans | Q44245252 | ||
| Mirtazapine for pruritus | Q44340894 | ||
| Involvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system | Q44342915 | ||
| Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. | Q44516252 | ||
| Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study | Q44903581 | ||
| Over-the-counter topical antipruritic agents are commonly recommended by office-based physicians: an analysis of US practice patterns | Q44941980 | ||
| The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers | Q45109636 | ||
| Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis | Q45157812 | ||
| Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial | Q45170301 | ||
| Idiopathic pruritus in psychiatric inpatients: an explorative study | Q45356090 | ||
| Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. | Q46005521 | ||
| A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients | Q46343813 | ||
| Antipruritic and thermal sensation effects of hydrocortisone creams in human skin | Q46390216 | ||
| Gabapentin for uraemic pruritus | Q46445941 | ||
| Pregabalin in the treatment of chronic pruritus. | Q46810840 | ||
| Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study | Q46832897 | ||
| Repetitive scratching and noxious heat do not inhibit histamine-induced itch in atopic dermatitis | Q46912125 | ||
| Gabapentin treatment for notalgia paresthetica, a common isolated peripheral sensory neuropathy | Q46933569 | ||
| Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study | Q48381465 | ||
| Assessing itch in children with atopic dermatitis treated with tacrolimus: objective versus subjective assessment | Q48467886 | ||
| Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients | Q48502316 | ||
| The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis | Q48710475 | ||
| Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases | Q48773204 | ||
| Central neuropathic itch: a new treatment option? | Q49047908 | ||
| Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice. | Q52575382 | ||
| Self-reported skin morbidity among adults: associations with quality of life and general health in a Norwegian survey. | Q53347151 | ||
| Brachioradial pruritus: treatment with topical capsaicin. | Q54343910 | ||
| Efficacy of naltrexone in the treatment of chronic refractory itching in burn patients: preliminary report of an open trial | Q57228285 | ||
| Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch | Q60678276 | ||
| Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin | Q60678303 | ||
| Sertraline as a first-line treatment for cholestatic pruritus | Q61480066 | ||
| Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin | Q62073550 | ||
| Topische Cannabinoidagonisten | Q62073553 | ||
| Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis | Q69652814 | ||
| Treatment of aquagenic pruritus with topical capsaicin cream | Q71606834 | ||
| Randomised crossover trial of naltrexone in uraemic pruritus | Q71849293 | ||
| Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria | Q72480897 | ||
| Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin | Q73382269 | ||
| Time-dependent variations of the skin barrier function in humans: transepidermal water loss, stratum corneum hydration, skin surface pH, and skin temperature | Q74020052 | ||
| Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study | Q78163535 | ||
| Putative mechanism of the itch-scratch circle: repeated scratching decreases the cutaneous level of prostaglandin D2, a mediator that inhibits itching | Q79653603 | ||
| Treatment of pruritus with topically applied opiate receptor antagonist | Q79826087 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1673-1682 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Therapy of pruritus | |
| P478 | volume | 11 |
| Q33928646 | A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers |
| Q38656850 | Advances in therapeutic strategies for the treatment of pruritus |
| Q35905999 | An Update on Treatment of Drug-Induced Liver Injury |
| Q26748628 | Anogenital Pruritus - An Overview |
| Q34549937 | Antipruritic effect of pretreatment with topical capsaicin 8% on histamine- and cowhage-evoked itch in healthy volunteers: a randomized, vehicle-controlled, proof-of-concept trial |
| Q41912557 | Characterization of the chloroquine-induced mouse model of pruritus using an automated behavioural system. |
| Q38841148 | Chemokine Receptor CXCR3 in the Spinal Cord Contributes to Chronic Itch in Mice |
| Q38549107 | Contact dermatitis: a comparative and translational review of the literature |
| Q37618589 | Diagnosis and Management of Chronic Pruritus: An Expert Consensus Review |
| Q37002814 | Electroacupuncture Attenuates 5'-Guanidinonaltrindole-Evoked Scratching and Spinal c-Fos Expression in the Mouse |
| Q35269209 | Enhanced nonpeptidergic intraepidermal fiber density and an expanded subset of chloroquine-responsive trigeminal neurons in a mouse model of dry skin itch. |
| Q60606792 | Histaminergic and non-histaminergic elicited itch is attenuated in capsaicin-evoked areas of allodynia and hyperalgesia: A healthy volunteer study |
| Q64973210 | Inhibitory Activity of Yokukansankachimpihange against Nerve Growth Factor-Induced Neurite Growth in Cultured Rat Dorsal Root Ganglion Neurons. |
| Q58595416 | Korean Red Ginseng extract and ginsenoside Rg3 have anti-pruritic effects on chloroquine-induced itch by inhibition of MrgprA3/TRPA1-mediated pathway |
| Q38452688 | Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out? |
| Q30428749 | Neural processing of itch |
| Q26752133 | Nocturnal Pruritus: The Battle for a Peaceful Night's Sleep |
| Q24197709 | Oral evening primrose oil and borage oil for eczema |
| Q34797205 | Physiological function of gastrin-releasing peptide and neuromedin B receptors in regulating itch scratching behavior in the spinal cord of mice |
| Q38837892 | Preclinical and human surrogate models of itch |
| Q35958649 | Pruritus in the elderly: clinical approaches to the improvement of quality of life |
| Q37272308 | Pruritus: an overview. What drives people to scratch an itch? |
| Q37902325 | Pruritus: management algorithms and experimental therapies. |
| Q64994702 | Real-World, Non-Interventional, Observational Study of Hydroxyzine Hydrochloride in Chronic Pruritus: a Prospective, Non-Comparative Study. |
| Q34294075 | Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system |
| Q34411838 | Somatosensory and vasomotor manifestations of individual and combined stimulation of TRPM8 and TRPA1 using topical L-menthol and trans-cinnamaldehyde in healthy volunteers |
| Q90624807 | The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera |
| Q35003120 | The role of central gastrin-releasing peptide and neuromedin B receptors in the modulation of scratching behavior in rats |
| Q34557234 | Topical capsaicin 8% for the treatment of neuropathic itch conditions |
| Q37902324 | Topical therapies for pruritus |
| Q60606795 | Topography of itch: evidence of distinct coding for pruriception in the trigeminal nerve |
| Q36703535 | Trp channels and itch |
| Q90326071 | Use of psychiatric drugs in dermatology |
| Q26865093 | Why we scratch an itch: the molecules, cells and circuits of itch |
Search more.